Codex DNA is a medical devices business based in the US. Codex DNA shares (DNAY) are listed on the NASDAQ and all prices are listed in US Dollars. Codex DNA employs 212 staff and has a trailing 12-month revenue of around $21 million.
Finder Award
eToro
Finder Award
SoFi Invest
| Latest market close | $1.76 |
|---|---|
| 52-week range | $1.08 - $11.02 |
| 50-day moving average | $1.44 |
| 200-day moving average | $2.27 |
| Wall St. target price | $6.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.84 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.76 from 2023-01-25
| 1 week (2023-01-19) | -11.11% |
|---|---|
| 1 month (2022-12-23) | 41.94% |
| 3 months (2022-10-26) | -1.68% |
| 6 months (2022-07-26) | -7.37% |
| 1 year (2022-01-26) | -74.34% |
|---|---|
| 2 years (2021-01-22) | N/A |
| 3 years (2020-01-22) | N/A |
| 5 years (2018-01-22) | N/A |
| Revenue TTM | $21 million |
|---|---|
| Gross profit TTM | $4.3 million |
| Return on assets TTM | -29.63% |
| Return on equity TTM | -67.7% |
| Profit margin | -251.05% |
| Book value | $1.81 |
| Market capitalisation | $38.4 million |
TTM: trailing 12 months
We're not expecting Codex DNA to pay a dividend over the next 12 months.
You may also wish to consider:
Codex DNA, Inc. , a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
